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ABSTRACT
Ageing is a process that inevitably affects most living organisms and
involves the accumulation of macromolecular damage, genomic
instability and loss of heterochromatin. Together, these alterations
lead to a decline in stem cell function and to a reduced capability to
regenerate tissue. In recent years, several genetic pathways and
biochemical mechanisms that contribute to physiological ageing have
been described, but further research is needed to better characterize
this complex biological process. Because premature ageing
(progeroid) syndromes, including progeria, mimic many of the
characteristics of human ageing, research into these conditions has
proven to be very useful not only to identify the underlying causal
mechanisms and identify treatments for these pathologies, but also
for the study of physiological ageing. In this Review, we summarize
the main cellular and animal models used in progeria research, with
an emphasis on patient-derived induced pluripotent stem cell models,
and define a series of molecular and cellular hallmarks that
characterize progeroid syndromes and parallel physiological
ageing. Finally, we describe the therapeutic strategies being
investigated for the treatment of progeroid syndromes, and their
main limitations.
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Introduction
The physiological deterioration that accompanies ageing constitutes
a major risk factor for the development of human pathologies, such
as cancer, cardiovascular disorders and neurodegenerative diseases
(Kennedy et al., 2014). Key molecular hallmarks of the ageing
phenotype include telomere attrition, genomic instability, loss of
proteostasis, epigenetic alterations, mitochondrial dysfunction,
deregulated nutrient sensing, stem cell exhaustion, cellular
senescence and altered intercellular communication (Lopez-Otin
et al., 2013). At the macromolecular level, ageing is characterized
by the development of wrinkles, greying and loss of hair,
presbyopia, osteoarthritis and osteoporosis, progressive loss of
fertility, loss of muscle mass and mobility, decreased cognitive
ability, hearing loss, and a higher risk for the development of cancer
and heart diseases, among other features (López-Otín et al., 2013).
Progeroid syndromes are a group of very rare genetic disorders
that are characterized by clinical features that mimic physiological
ageing, such as hair loss, short stature, skin tightness, cardiovascular
diseases and osteoporosis. Consequently, they constitute a relevant
source of information to understand the molecular mechanisms
involved in normal ageing. Progeroid disorders do not show
differences in prevalence depending on sex or ethnic origin, and
appear at an early age, mainly due to defects in the nuclear envelope
and DNA repair mechanisms (Gordon et al., 2014). Affected
individuals die at a young age, usually as a consequence of
cardiovascular problems and musculoskeletal degeneration.
In this Review, we classify human progeroid syndromes into two
main groups according to the mechanisms that underlie the disease.
Next, we discuss recent findings in the study of progeroid
syndromes, achieved through the use of cellular and animal
models. On the basis of these findings, we propose nine candidate
hallmarks of premature ageing, and highlight their similarities with
those described for physiological ageing. These proposed hallmarks
recapitulate the most remarkable characteristics of progeroid
syndromes and define the mechanisms underlying their
pathogenesis, which could provide ideas for future studies on
both physiological and pathological ageing. Finally, we review
different therapeutic strategies developed for the treatment of these
rare but devastating diseases.
A classification system for human progeroid syndromes
All progeroid syndromes are characterized by similar clinical features
(Table 1), but their underlying mechanisms can vary depending on
the mutated gene and the pathway that is consequently altered.
Below, we have classified progeroid syndromes into two general
categories based on the molecular pathway involved. The first group
includes those syndromes caused by alterations in components of the
nuclear envelope, such as Hutchinson-Gilford progeria syndrome
(HGPS), Néstor-Guillermo progeria syndrome (NGPS), atypical
progeria syndromes (APSs), restrictive dermopathy (RD) and
mandibuloacral dysplasia (MAD). The second group consists of
progeroid syndromes induced by mutations in genes involved in
DNA-repair pathways, such as Werner syndrome (WS), Bloom
syndrome (BS), Rothmund-Thomson syndrome (RTS), Cockayne
syndrome (CS), xeroderma pigmentosum (XP), trichothiodystrophy
(TTD), Fanconi anaemia (FA), Seckel syndrome (SS), ataxia
telangiectasia (AT), ataxia telangiectasia-like disorder (ATLD),
cerebroretinal microangiopathy with calcifications and cysts
(CRMCC), and Nijmegen breakage syndrome (NBN). A
subcategory of this group comprises dyskeratosis congenita (DC)
and Hoyeraal-Hreidarsson syndrome (HHS), linked to mutations in
components of the telomerase complex (see Box 1 for a glossary of
terms) that cause telomere attrition.
Nuclear architecture instability and premature ageing
The nuclear lamina is a highly regulated membrane barrier that
separates the nucleus from the cytoplasm in eukaryotic cells, and
contains lamins and other proteins involved in chromatin
organization and gene regulation (Burke and Stewart, 2013)
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Table 1. Clinical features of progeroid syndromes
Syndrome Phenotype Gene Function References
HGPS Alopecia, atherosclerosis, prominent
scalp veins, lipodystrophy, heart
infarction and death during puberty
LMNA Regulates nuclear assembly,
chromatin organization, and
nuclear-membrane and telomere
maintenance
Gordon et al.,
2014;
Hennekam,
2006
APSs Short stature, prominent nose,
premature hair greying, partial
alopecia, skin atrophy, lipodystrophy
and skeletal anomalies
LMNA Regulates nuclear assembly,
chromatin organization, and
nuclear-membrane and telomere
maintenance
Barthelemy et al.,
2015
RD Intrauterine growth retardation, facial
deformities, enlarged fontanelles,
tightly adherent skin, low bone
density, dysplasia of clavicles and
congenital contractures
ZMPSTE24 Proteolytically removes three C-
terminal residues of farnesylated
lamin A/C
Navarro et al.,
2005; Thill et al.,
2008
MADA Growth retardation, skeletal and
craniofacial anomalies, osteolysis,
pigmentary skin changes and partial
lipodystrophy
LMNA Regulates nuclear assembly,
chromatin organization, and
nuclear-membrane and telomere
maintenance
Novelli et al., 2002
MADB Generalized lipodystrophy, prominent
eyes, beaked nose, hair loss, mottled
hyperpigmentation, acro-osteolysis
and joint contractures
ZMPSTE24 Proteolytically removes three C-
terminal residues of farnesylated
lamin A/C
Agarwal et al.,
2003
NGPS Early onset, lipoatrophy, severe
osteolysis and alopecia
BANF1 Regulates nuclear assembly,
chromatin organization, gene
expression and gonad
development
Cabanillas et al.,
2011
WS Short stature, skin tightness and
ulcerations, hair greying,
lipodystrophy, osteoporosis, bilateral
cataracts, heart disease, and
calcification of cardiac valves
WRN Unwinds double-strand DNA,
contributes to reparation of
DSBs, and intervenes in NHEJ,
HR and BER DSBs. Also
involved in telomere
maintenance and replication
Huang et al., 2006
BS Prenatal growth retardation, light
sensitivity, telangiectatic skin
lesions, reduced fertility,
predisposition to cancer, and
immunodeficiency
BLM Unwinds single- and double-strand
DNA, and participates in DNA
replication and DSB repair
Ellis et al., 2008
RTS Greying of hair, juvenile cataracts, and
skin and skeletal abnormalities
RECQL4 DNA-dependent ATPase involved
in DNA repair and chromosome
segregation
Puzianowska-
Kuznicka and
Kuznicki, 2005
CS Impaired development of the neural
system, eye abnormalities,
microcephaly, photosensitivity and
premature ageing
ERCC6, ERCC8 Involved in transcription-coupled
NER, which allows RNA-
polymerase-II-blocking lesions to
be removed from the transcribed
strand of active genes
Tan et al., 2005
XP Skin photosensitivity, photophobia and
no neurological abnormalities
XPA, XPB, XPC, XPG
DDB2, ERCC4, ERCC6,
POLH
Involved in NER (particularly in
cyclobutane pyrimidine dimers
repair) and in homologous
recombination
Cleaver, 2005
TTD Brittle hair, skin photosensitivity, growth
retardation, neurological
abnormalities and a reduced life
expectancy
XPB, XPD, TFB5 Involved in NER (particularly in
cyclobutane pyrimidine dimers
repair)
Itin et al., 2001
FA Higher cancer susceptibility, bone-
marrow failure, short stature, skin
abnormalities and developmental
disabilities
BRCA2, BRIP1, FANCA,
FANCB, FANCC,
FANCD2, FANCE,
FANCF, FANCG, FANCI,
FANCL, FANCM, PALB2,
RAD51C, SLX4
Involved in repairing interstrand
cross-links during replication and
in the maintenance of
chromosomal stability
Bogliolo and
Surralles, 2015
SS Intrauterine growth retardation and
postnatal dwarfism with a small, bird-
like face
ATR Acts as a DNA damage sensor by
activating checkpoint signalling
upon genotoxic stresses
Pennarun et al.,
2010
AT Progressive cerebellar degeneration,
pigmentary abnormalities,
ATM Acts as a DNA damage sensor by
activating checkpoint signalling
Sahin and
Depinho, 2010
Continued
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(Fig. 1). There are two major types of lamin proteins, the A-type,
encoded by the gene LMNA, which includes lamins A and C, and
the B-type, encoded by the genes LMNB1 and LMNB2, and includes
lamins B1, B2 and B3. Lamin A undergoes complex post-
translational processing steps, such as farnesylation, cleavage by
the zinc metallopeptidase STE24 (ZMPSTE24), carboxyl
methylation by the isoprenylcysteine carboxylmethyltransferase
(ICMT), and excision of the farnesylated residue (Fig. 1). Lamin A
also interacts with many different proteins, such as the barrier to
autointegration factor (BAF), to achieve mitotic and post-mitotic
nuclear assembly (Jamin and Wiebe, 2015). Mutations in genes that
encode nuclear-lamina proteins cause progeroid syndromes, such as
HGPS, NGPS, APSs, RD and MAD (Agarwal et al., 2003;
Barthelemy et al., 2015; De Sandre-Giovannoli et al., 2003;
Eriksson et al., 2003; Navarro et al., 2005; Puente et al., 2011). In
this section, we describe the main clinical features of progeroid
syndromes caused by mutations in key elements of the nuclear
envelope (Table 1).
Hutchinson-Gilford progeria syndrome
HGPS is the most prevalent and widely studied accelerated-ageing
syndrome. Most cases of HGPS originate from a de novo
heterozygous silent mutation in the LMNA gene (G608G). This
mutation activates a cryptic splicing site (Box 1) that results in the
deletion of 50 amino acids near the C-terminus of prelamin A,
which encompasses the final cleavage site for CAAX prenyl
protease 1 homolog (ZMPSTE24) to produce lamin A. This leads to
the accumulation of a toxic protein called progerin, which disrupts
the integrity of the nuclear envelope (Fig. 1) (De Sandre-Giovannoli
et al., 2003; Eriksson et al., 2003). Individuals with HGPS display
alopecia (hair loss), atherosclerosis, lipodystrophy, heart infarction
and death during puberty (Table 1) (Gordon et al., 2014). Cells
derived from these individuals present nuclear shape abnormalities
known as ‘blebs’ (Fig. 1B) and shortened telomeres, and undergo
premature senescence as a consequence of genome instability
(Gonzalo and Kreienkamp, 2015). Progerin also accumulates
during physiological ageing, reinforcing the parallels between
normal and pathological ageing (Scaffidi and Misteli, 2006).
Similar to aged individuals, HGPS individuals demonstrate vascular
stiffening, atherosclerotic plaques and calcium dysfunction
(Gerhard-Herman et al., 2012; Olive et al., 2010). Nonetheless,
some basic features of ageing, such as the deterioration of the
nervous system, the immune system deficits and the increased
susceptibility to cancer, are not recapitulated in HGPS (Gordon
et al., 2014). This is due to the low levels of prelamin A expression
in the brain (Jung et al., 2012), and to the presence of a tumour
Table 1. Continued
Syndrome Phenotype Gene Function References
telangiectasia atrophy, hair greying,
immunodeficiency and cancer
susceptibility
upon DSBs, apoptosis and
genotoxic stresses
CRMCC Progressive intracranial calcifications,
brain cysts, leukodystrophy,
spasticity, ataxia, cognitive decline,
osteopenia and bone fractures
CTC1 Part of the CST complex,
associated with telomere
maintenance
Bisserbe et al.,
2015
ATLD Progressive cerebellar degeneration,
ataxia and oculomotor apraxia, but
no immunodeficiency nor
telangiectases
MRE11A Component of the MRN complex,
implicated in DSB repair, DNA
recombination, maintenance of
telomere integrity, cell cycle
checkpoint control and meiosis
Fernet et al., 2005
NBN Progressive microcephaly, intrauterine
growth retardation, short stature,
recurrent sinopulmonary infections,
increased cancer risk and premature
ovarian failure in females
NBN Component of the MRN complex,
implicated in DSB repair, DNA
recombination, maintenance of
telomere integrity, cell cycle
checkpoint control and meiosis
Seemanova et al.,
2006
DC Bone marrow failure, abnormal skin
pigmentation, cancer predisposition,
pulmonary and hepatic fibrosis,
leukoplakia, nail dystrophy,
thrombocytopenia, premature hair
greying, osteoporosis and testicular
atrophy
TERC, TERT, WRAP53,
CTC1
TERC, TERT and WRAP53 are
components of the telomerase
complex, involved in replication
of chromosome termini, whereas
CTC1 is part of the CST complex,
associated with telomere
maintenance
Stanley and
Armanios, 2015
HHS Intrauterine growth retardation,
microcephaly, bone-marrow failure,
immunodeficiency, cerebellar
hypoplasia and enteropathy
RTEL1, ACD RTEL1 is implicated in telomere-
length regulation, DNA repair and
maintenance of genomic
stability, whereas ACD encodes
TPP1, a component of the
shelterin complex, involved in
telomere length regulation
Walne et al., 2013
HGPS, Hutchinson-Gilford progeria syndrome; APSs, atypical progeroid syndromes; RD, restrictive dermopathy; MADA, mandibuloacral dysplasia type A;
MADB, mandibuloacral dysplasia type B; NGPS, Néstor-Guillermo progeria syndrome;WS, Werner syndrome; BS, Bloom syndrome; RTS, Rothmund-Thomson
syndrome; CS, Cockayne syndrome; XP, xeroderma pigmentosum; TTD, trichothiodystrophy; FA, Fanconi anaemia; SS, Seckel syndrome; AT, ataxia
telangiectasia; CRMCC, cerebroretinal microangiopathy with calcifications and cysts; ATLD, ataxia telangiectasia-like disorder; NBN, Nijmegen breakage
syndrome; DC, dyskeratosis congenita; HHS, Hoyeraal-Hreidarsson syndrome; DSB, double-strand break; NHEJ, non-homologous end joining; HR,
homologous recombination; BER, base excision repair; NER, nucleotide excision repair; CST, CTC1, STN1 and TEN1 complex; MRN, MRE11, RAD50,
NBS1 complex.
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protection mechanism mediated by bromodomain containing
protein 4 (BRD4) in cells from individuals with HGPS
(Fernandez et al., 2014) (discussed in more detail later).
Atypical progeria syndromes
Several lamin A mutations, including A57P, R133L and L140R,
which are predicted to alter key protein-protein interaction domains,
are associated with APSs. Individuals with APS show many of the
clinical features of HGPS (Table 1), but their cells do not
accumulate prelamin A or progerin (Barthelemy et al., 2015).
Restrictive dermopathy and mandibuloacral dysplasia
RD is a rare recessive condition caused by ZMPSTE24 mutations
that lead to the accumulation of lamin A precursors (Navarro et al.,
2005). MAD is characterized by lipodystrophy and skeletal and
metabolic abnormalities (Table 1). MADwith type A lipodystrophy
(MADA) is induced by the homozygous R527H LMNA mutation,
which leads to accumulation of prelamin A and changes in nuclear
architecture (Novelli et al., 2002), whereas MAD with type B
lipodystrophy (MADB) is caused by compound heterozygous
mutations in ZMPSTE24 (Agarwal et al., 2003).
Néstor-Guillermo progeria syndrome
NGPS is caused by a homozygous mutation (c.34G<A; p.
Ala12Thr) in BANF1 (barrier to autointegration Factor 1), which
encodes the protein BAF, involved in chromatin organization,
nuclear assembly and gene-expression regulation. Fibroblasts from
NGPS individuals demonstrate reduced levels of BAF protein,
aberrant nuclear morphology, namely blebbing (Fig. 1), and altered
subcellular distribution of emerin (see Box 1) (Cabanillas et al.,
2011; Puente et al., 2011). The A12T mutation also weakens the
binding of BAF to DNA, which is crucial for its many roles in the
cell, suggesting that this deficiency contributes to the cellular
phenotype observed in NGPS (Paquet et al., 2014). NGPS shares
many clinical features with HGPS (Table 1), but, for unknown
reasons, lacks cardiovascular defects, which likely contributes to the
longer lifespan of NGPS patients (Cabanillas et al., 2011).
Defects in DNA repair, and premature ageing
Damage to nuclear DNA is a direct cause of ageing and cancer, and
a decline in DNA repair with age has been described (Vijg and Suh,
2013). Moreover, many progeroid syndromes are caused by defects
in DNA repair (Childs et al., 2014; Vermeij et al., 2016). In humans,
there are five RecQ helicases – proteins that repair double-strand
breaks during DNA replication (Box 1), and maintain genome
stability and telomere integrity (Bernstein et al., 2010). Mutations in
three of them [WRN (Werner syndrome, RecQ helicase-like), BLM
(Bloom syndrome, RecQ helicase-like) and RECQ4 (RecQ
helicase-like 4)] are associated with WS, BS and RTS premature-
ageing syndromes, respectively. Other DNA-repair proteins altered
in progeroid syndromes include the excision-repair cross-
complementing (ERCC) family, the FA proteins and the XP
proteins, which collaborate to enable DNA nucleotide excision
repair (NER) and double-strand-break repair (Fig. 2; Box 1)
(Vermeij et al., 2016). Mutations in genes encoding these and other
proteins involved in DNA repair are responsible for different
premature-ageing disorders, the clinical features of which are
summarized below and in Table 1.
Werner syndrome
WS is caused by mutations in the WRN gene that result in the
production ofWRN truncated proteins (Yu et al., 1996). Individuals
with this disorder display a range of premature-ageing symptoms
(Table 1) and a high incidence of cancer that might be related to the
chromosomal instability, telomere dysfunction and senescent
phenotype exhibited by cells lacking WRN (Crabbe et al., 2007).
Bloom syndrome
BS is caused by mutations in the BLM gene, which encodes the
RecQ helicase BLM. These mutations lead to the mislocalization of
BLMprotein or to the impairment of its helicase or ATPase domains
(Machwe et al., 2005). This syndrome is characterized by
immunodeficiency and predisposition to cancer, among other
features (Table 1) (Ellis et al., 2008).
Box 1. Glossary
Emerin: protein encoded by the EMD gene. Present in the inner nuclear
membrane in vertebrates, and highly expressed in cardiac and skeletal
muscle. Mutations in emerin cause X-linked recessive Emery-Dreifuss
muscular dystrophy, cardiac conduction abnormalities and dilated
cardiomyopathy.
Cryptic splice site: splice sites that are usually dormant and can be
activated by nearby mutations, often causing genetic diseases.
CST complex: a complex involved in termination of telomere elongation,
composed of CTC1, STN1 and TEN1.
Double-strand break (DSB) repair: double-strand breaks (DSBs) can
lead to genome rearrangements. Three mechanisms exist to repair
DSBs: non-homologous end joining (NHEJ), microhomology-mediated
end joining (MMEJ) and homologous recombination (HR).
Interstrand crosslinks (ICLs): highly toxic DNA lesions that prevent
transcription and replication by inhibiting DNA strand separation.
Multipotent cell: progenitor cell that has the gene activation potential to
differentiate into multiple, but limited, cell types.
Nucleotide excision repair (NER): DNA-repair mechanism that
removes DNA damage induced by ultraviolet (UV) light, mostly
thymine dimers and 6,4-photoproducts.
Pluripotent cell: stem cell that has the potential to differentiate into any
of the three germ layers: endoderm, mesoderm and ectoderm.
RecQ helicase family: helicases are enzymes important in replication
and genomemaintenance that unwind paired DNA and translocate in the
3′-to-5′ direction.
Shelterin complex: protein complex that protects mammalian telomeres
from DNA-repair mechanisms, in addition to regulating telomerase
activity. Subunits of shelterin bind to telomeres and induce the
formation of a t-loop, a cap structure that prevents DNA-damage-
sensing machinery from mistakenly repairing telomeres. The absence
of shelterin causes telomere uncapping and thereby activates damage-
signalling pathways that can lead to NHEJ, HR, senescence or apoptosis.
Shelterin has six subunits: TRF1, TRF2, POT1, RAP1, TIN2 and TPP1.
Somatotropic axis: consists of growth hormone (GH) and insulin-like
growth factors (IGF-I and -II) together with their associated carrier
proteins and receptors. Regulates metabolism and other physiological
processes. Other hormones, such as insulin, leptin, glucocorticoids and
thyroid hormones, modulate GH and IGF synthesis and availability.
Telomerase complex: ribonucleoprotein complex encoded by the
TERT, TERC, DKC1 and TEP1 genes that enlarges telomeres by
adding the polynucleotide ‘TTAGGG’ to their 3′ end thanks to its reverse
transcriptase activity, so that they can protect the ends of the
chromosomes from deterioration or from fusionwith other chromosomes.
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Rothmund-Thomson syndrome
RTS is caused by mutations in RECQL4, which encodes a helicase
localized at telomeres and mitochondria (Croteau et al., 2012). This
syndrome is mainly characterized by growth deficiency, skin
abnormalities and increased susceptibility to cancer (Table 1)
(Puzianowska-Kuznicka and Kuznicki, 2005). The loss of RECQL4
in fibroblasts of affected individuals leads to impaired DNA repair
after oxidative stress and to growth arrest, which could explain the
dwarfism associated with this disorder (Werner et al., 2006).
Cockayne syndrome, xeroderma pigmentosum and trichothiodystrophy
CS, XP and TTD are a group of related disorders associated with
defects in NER (Box 1) (Marteijn et al., 2014). CS is a
neurodegenerative disorder caused by mutations in the ERCC6
and ERCC8 genes, and is mainly characterized by neural
abnormalities and growth failure (Table 1) (Tan et al., 2005). XP
arises frommutation of any of many different genes, including XPA,
XPB, XPC, XPG, ERCC4, ERCC6, DDB2 and POLH. This
syndrome is characterized by an impaired capacity to repair the
damage caused by UV light, which leads to increased cancer
susceptibility (Cleaver, 2005). TTD is another rare progeroid
disorder generated by mutations in XPB, XPD or TFB5, and is
characterized by skin photosensitivity, growth retardation and a
reduced life expectancy (Itin et al., 2001).
Fanconi anaemia
Mutations in FA genes, which encode proteins that are involved in
DNA repair, such as FANCA or BRCA2, can lead to FA disease.
Individuals with FA exhibit a higher cancer susceptibility, bone
marrow failure, short stature, skin abnormalities and developmental
disabilities (Table 1) (Deakyne and Mazin, 2011). Cells from
individuals with FA produce high levels of reactive oxygen species
(ROS), which can damage telomeric regions (Uziel et al., 2008). This
defect, together with an insufficient DNA-repair system, results in
single-strandDNAbreaks that induce accelerated telomere shortening.
Mutant cells show shorter telomeres and an increase in chromosome-
end fusions compared to normal controls, resulting in genomic
instability and multinucleated cells (Bogliolo and Surralles, 2015).
Seckel syndrome
SS is caused by mutations in the ATR (ataxia telangiectasia and
Rad3-related) gene, which codes for the serine/threonine kinase
ATR. SS is characterized by intrauterine growth retardation and
postnatal dwarfism (Table 1) (Shanske et al., 1997). ATR protein
has a crucial role in preventing replicative stress, sensing DNA
damage and consequently arresting the cell cycle, and in
maintaining telomere integrity (Pennarun et al., 2010).
Ataxia telangiectasia
AT is caused by mutations in the ATM (ataxia telangiectasia
mutated) gene, which encodes a serine/threonine kinase that is
activated by DNA double-strand breaks. AT individuals show
progressive cerebellar degeneration, pigmentary abnormalities, hair
greying and increased cancer susceptibility (Table 1). ATM is
involved in DNA-damage signalling, cell cycle arrest and telomere
maintenance (Sahin and DePinho, 2010).
Dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome
Telomere shortening is observed during normal ageing both in
human and mouse cells, acting as a barrier to tumour growth and
Methylation
C-terminal
cleavage
Farnesylation
Control
A  Normal prelamin A processing B  Abnormal prelamin A processing
Methylation
C-terminal
cleavage
Farnesylation
Progerin
Prelamin APrelamin A
Lamin A
Nuclear envelope
Final
cleavage
Fig. 1. Prelamin A physiological and
pathological processing and maturation.
Processing of prelamin A in (A) normal cells,
leading to the generation of mature lamin A and
assembly of the normal nuclear envelope, and (B)
HGPS cells, where the HGPS-associatedmutation
(G608G) in the gene encoding prelamin A, LMNA,
activates a cryptic splicing site that results in the
deletion of 50 amino acids slightly upstream of the
C-terminus of prelamin A, encompassing the final
cleavage site for ZMPSTE24 and leading to the
accumulation of a toxic form of lamin A named
progerin. This leads to disruption of the nuclear
envelope, detectable as bulging or ‘nuclear
blebbing’, which is shown in the representative
images of HGPS and NGPS human fibroblasts
illustrated below, in comparison to control cells.
Lamin A/C (green) and DAPI (blue) staining is
shown. Note that nuclear blebbing in NGPS cells is
not due to the accumulation of progerin (see main
text), and this image has been included purely to
demonstrate the phenotype. FTase,
farnesyltransferase; ICMT, isoprenylcysteine
carboxyl methyltransferase; HGPS, Hutchinson-
Gilford progeria syndrome; NGPS, Nestor-
Guillermo progeria syndrome; ZMPSTE24, zinc
metalloproteinase STE24.
723
REVIEW Disease Models & Mechanisms (2016) 9, 719-735 doi:10.1242/dmm.024711
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
contributing to cell senescence (Armanios and Blackburn, 2012).
Various premature ageing disorders, such as DC and HHS, are
linked to mutations in components of the telomerase complex
(Box 1). DC is a rare autosomal-dominant disorder caused by
mutations in TERC (telomerase RNA component), TERT
(telomerase reverse transcriptase), WRAP53 (WD repeat
component, antisense to TP53) or CTC1 (CTS telomere
maintenance complex component 1), among other genes (Stanley
and Armanios, 2015). X-linked DC is caused bymutations inDKC1
(dyskeratosis congenita 1) (Fig. 2) (Yoon et al., 2006). Individuals
with DC present bone marrow failure, cancer predisposition,
premature hair greying and osteoporosis (Table 1) (Stanley and
Armanios, 2015). HHS is a very rare multisystem disorder that
phenocopies DC but with an increased severity (Table 1) (Walne
et al., 2013). Mutations responsible for HHS have been identified in
RTEL1 (regulator of telomere elongation helicase 1), which encodes
a helicase that is essential for telomere maintenance, and ACD
(adrenocortical dysplasia homolog), which encodes the shelterin
TPP1 (Box 1) (Kocak et al., 2014; Walne et al., 2013).
The development of cellular and mouse models for the study
of the progeroid syndromes described above has been extremely
useful in order to elucidate the mechanisms underlying such
diseases. The most relevant models are described in the following
sections.
Cellular models of progeroid syndromes
The generation of patient-derived induced pluripotent stem cells
(iPSCs) in recent years has enabled researchers to study specific
tissues affected by a disease and to discover new tissue-specific
drugs (Studer et al., 2015; Tang et al., 2016). Recently, these
approaches have also been used to study different progeroid
syndromes and to identify barriers to reprogramming in normally
aged and prematurely aged cells.
iPSC generation from progeroid cells
iPSCs from several progeroid syndromes have been successfully
generated and differentiated along multiple lineages (Table 2).
However, progeria-derived iPSCs normally show reduced
reprogramming efficiency in comparison to control cells despite
being indistinguishable from normal iPSCs in other ways. In line
with this, HGPS and NGPS iPSCs lack disease-specific features,
such as nuclear blebs, epigenetic changes or, in the case of HPGS
iPSCs, progerin expression, demonstrating the erasure of age-
associated marks (Lo Cicero and Nissan, 2015; Soria-Valles et al.,
2015a; Xiong et al., 2013). Once differentiated, however, the
progeroid iPSC-derived cells show age-associated alterations,
frequently mimicking the associated pathologies. These iPSC-
derived models have been useful for studying the molecular
mechanisms of HGPS and NGPS progerias and for screening drug
candidates that could be used to treat these disorders (Pitrez et al.,
2016; Soria-Valles et al., 2015b). Likewise, whenWS fibroblasts are
reprogrammed, their telomeres elongate, indicating that telomere
function is restored (Shimamoto et al., 2014). The differentiation of
WS iPSCs tomesenchymal stem cells (MSCs) results in a recurrence
of premature senescence that is associated with telomere attrition.
This phenotype can be rescued by the expression of hTERT or by
knocking down p53 (Cheung et al., 2014). Another study, using
iPSCs generated from CS fibroblasts, has demonstrated that lack of
functional ERCC6 increases cell death and ROS production, and
upregulates TP53 relative to normal cells (Andrade et al., 2012).
XP iPSCs from patients with mutations in XPA have also been
developed to produce in vitro models of neurological disorders (Fu
C  NER
A  DSB repair B  ICL repair
D  Telomere dynamics
TERC
Fig. 2. Mutations in proteins involved in DNA repair lead to premature ageing syndromes. Diagrams of the proteins involved in (A) double-strand break
(DSB) repair, (B) interstrand cross-link (ISL) repair, (C) nucleotide excision repair (NER) and (D) telomere elongation and maintenance, including the shelterin
complex, the telomerase complex and the CST (CTC1, STN1 and TEN1) complex (Box 1). Proteins encoded by genes mutated in progeroid syndromes are
shown in orange, blue, green and red, whereas non-mutated proteins are shown in grey.
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et al., 2016). These iPSCs can be differentiated into neural cells,
indicating that the expression of wild-type XPA alleles is not required
for iPSC generation and differentiation (Ohnishi et al., 2015). Studies
with DC-derived iPSCs have shown that, even in the undifferentiated
state, these cells can exhibit substantially reduced telomerase levels or
mislocalization of telomerase from Cajal bodies to nucleoli, which
disables the telomere elongation that normally accompanies
reprogramming (Batista et al., 2011). Notably, iPSCs from
fibroblasts of individuals with FANCA mutations have an impaired
ability to differentiate towards early hemoangiogenic progenitors,
which indicates that the hematopoietic phenotype of individuals with
FA originates from an early hematopoietic stage (Suzuki et al., 2015).
Correction of the FANCA mutation increases reprogramming and
differentiation capacities of the resulting cells (Raya et al., 2009).
AT-derived fibroblasts have also been reprogrammed, albeit at a
reduced efficiency (Fukawatase et al., 2014). These iPSCs display
hypersensitivity to ionizing radiation, alterations in DNA-damage
signalling pathways, metabolic changes and cell cycle checkpoint
defects. AT-derived iPSCs have been differentiated into functional
neurons, providing a unique model for the study of AT-associated
neurodegeneration (Nayler et al., 2012).
Surprisingly, iPSCs have not yet been derived from RD, MAD,
RTS, TTD, BS or SS cells, nor fromAPSs. The reason for this might
partly rest with the low reprogramming efficiency of progeroid cells
owing to a series of reprogramming barriers that are starting to be
elucidated, as discussed below.
Barriers to reprogramming in ageing cells
Several features displayed by aged cells, such as genetic damage,
telomere shortening and cell senescence, represent barriers that
greatly reduce the efficiency of cell reprogramming. The
reprogramming process is slow and inefficient in part because the
forced expression of the Yamanaka factors is a stressful mechanism
that activates apoptosis and cellular senescence via the upregulation
of tumour suppressor proteins, including p53, p16 (INK4a) and p21
(CIP1) (Li et al., 2009). Accordingly, the inhibition of these factors
improves reprogramming efficiency (Banito and Gil, 2010; Hong
et al., 2009). Metabolic studies also indicate that inhibition of
mammalian target of rapamycin (mTOR) notably improves the
efficiency of iPSC generation (Chen et al., 2011), identifying
mTOR as an important repressor of reprogramming.
Interestingly, NF-κB (nuclear factor kappa-light-chain-enhancer
of activated B cells) activation constitutes another barrier to somatic
cell reprogramming in normally and prematurely aged cells (Soria-
Valles et al., 2015a). Accordingly, NF-κB inhibition significantly
increased the reprogramming efficiency of NGPS and HGPS
fibroblasts, and of fibroblasts from advanced-age donors. Progeroid
fibroblasts also showed a noticeable overexpression of DOT1L
(DOT1-like histone H3-K79 methyltransferase), induced by
NF-κB. Consistent with this, DOT1L inhibition increased
reprogramming efficiency of progeroid cells and physiologically
aged fibroblasts. Remarkably, treatment of progeroid mice with
DOT1L inhibitors extends their longevity, implicating DOT1L as a
newly identified target for rejuvenation-based approaches (Soria-
Valles et al., 2015b).
Cells from individuals with FA failed to be reprogrammed to
iPSCs unless the defective FA gene was replaced (Muller et al.,
2012; Raya et al., 2009). However, a recent study has revealed that
E6 protein from human papillomavirus 16 (HPV16) rescues FA-
derived iPSC colony formation via p53 inhibition (Chlon et al.,
2014). Consequently, the FA pathway is required for
reprogramming through p53-dependent mechanisms, emphasizing
the importance of classical tumour suppressors as barriers for cell
reprogramming in progeroid syndromes.
Table 2. Progeroid-syndrome-derived iPSCs
Syndrome Gene Mutation Donor cells Differentiated into References
HGPS LMNA G608G Fibroblasts MSCs, dermal cells, neural cells Nissan et al., 2012
HGPS LMNA G608G Fibroblasts Fibroblasts Ho et al., 2011
HGPS LMNA G608G Fibroblasts VSMCs, fibroblasts Liu et al., 2011
HGPS LMNA G608G Fibroblasts SMCs Zhang et al., 2014
HGPS LMNA G608G Fibroblasts Endothelial cells, neural cells, fibroblasts,
VSMCs, MSCs
Zhang et al., 2011
HGPS LMNA G608G Fibroblasts Adipocytes Xiong et al., 2013
NGPS BANF1 A12T Fibroblasts MSCs Soria-Valles et al., 2015a
APSs LMNA E578V Fibroblasts Fibroblasts Ho et al., 2011
WS WRN R369* Fibroblasts Embryoid bodies Shimamoto et al., 2014
WS WRN F1074L, R368X Fibroblasts MSCs and NSCs Cheung et al., 2014
CS ERCC6 R735X Fibroblasts Embryoid bodies Andrade et al., 2012
XP XPA R228*
C619T
Fibroblasts Neural lineage Ohnishi et al., 2015
Fu et al., 2016
XP XPB T296C Fibroblasts Neural lineage Fu et al., 2016
XP XPC IVS3-9T>C Fibroblasts Neural lineage Fu et al., 2016
XP ERCC5 c.2172delA Fibroblasts Neural lineage Fu et al., 2016
XP POLH C376T Fibroblasts Neural lineage Fu et al., 2016
FA FANCA c.2546delC
c.3931-3932del
Fibroblasts Hematopoietic cells Suzuki et al., 2015
FA FANCA Unknown Fibroblasts Hematopoietic cells Raya et al., 2009
AT ATM c.7004delCA
c. 7886delTATTA
Fibroblasts Neurons Nayler et al., 2012
AT ATM IVS31+2T >A Fibroblasts Neurons Fukawatase et al., 2014
DC TERT P704S, R979W Fibroblasts ND Batista et al., 2011
DC DKC1 L54V, ΔL37 Fibroblasts ND Batista et al., 2011
DC TCAB1 H376Y/G435R Fibroblasts ND Batista et al., 2011
HGPS, Hutchinson-Gilford progeria syndrome; NGPS, Néstor-Guillermo progeria syndrome; APSs, atypical progeroid syndromes; WS, Werner syndrome; CS,
Cockayne syndrome; XP, xeroderma pigmentosum; FA, Fanconi anaemia; AT, ataxia telangiectasia; DC, dyskeratosis congenita; MSCs, mesenchymal stem
cells; VSMCs, vascular smooth muscle cells; SMCs, smooth muscle cells; NSCs, neural stem cells; ND, not differentiated.
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Mouse models of progeroid syndromes
Mouse models have been widely used to explore the molecular
mechanisms of ageing and progeroid syndromes. Thus, experiments
using mice with an extended lifespan or with signs of premature
ageing have helped to elucidate the basic processes that affect ageing
(Table 3) (Lopez-Otin et al., 2013; Vanhooren and Libert, 2013).
In 2002, Pendás et al. and Bergo et al., developed the first
HGPS mouse model – Zmpste24-null (Zmpste24−/−) mice – which
showed growth retardation, cardiomyopathy, muscular dystrophy,
lipodystrophy and premature death (Bergo et al., 2002; Pendas et al.,
2002). Studies of these mice demonstrated that the accumulation of
farnesylated prelamin A damages the nuclear envelope,
hyperactivates p53 signalling, and causes cellular senescence,
stem cell dysfunction and a progeroid phenotype (Osorio et al.,
2009; Varela et al., 2005). Zmpste24−/− mice are also defective in
DNA repair (Liu et al., 2005), and in the p53-dependent
upregulation of miR-29, which represses extracellular matrix
genes (Ugalde et al., 2011). Extracellular matrix remodelling is a
widely known mechanism that promotes renovation of adult tissues,
and, consequently, repression of such genes impairs tissue
restoration and promotes ageing (Gutierrez-Fernandez et al.,
2015). However, this mouse model cannot be used to study the
aberrant splicing of LMNA observed in individuals with HGPS,
prompting the generation of a mouse strain that carries the
HGPS mutation (LMNAG608G) (Osorio et al., 2011). These mice
accumulate progerin and phenocopy the main clinical
manifestations of human HGPS, such as shortened lifespan and
bone and cardiovascular alterations. This model has been widely
used to develop new therapeutic strategies for HGPS.
Other mouse models related to the lamin-A–Zmpste24 system
have helped to elucidate why individuals with HGPS are not
predisposed to cancer despite their elevated levels of DNA damage
(Cau et al., 2014; Gordon et al., 2014). Zmpste24 mosaic mice that
contain both Zmpste24-proficient cells and Zmpste24−/− cells have
revealed a lower incidence of invasive carcinomas compared to
mice that are heterozygous for Zmpste24 (de la Rosa et al., 2013).
Parallel studies have described another cancer protective
mechanism in HGPS cells involving suppression of cell
proliferation and metastatic properties owing to an altered pattern
of chromatin binding by the transcription regulator BRD4
(Fernandez et al., 2014). Other mouse models with Lmna
mutations have been developed, although many of these do not
fully recapitulate the progeroid phenotype observed in HGPS or
APSs (Das et al., 2013; Poitelon et al., 2012; Varga et al., 2006).
Zmpste24−/− mouse models have been used to study the molecular
mechanisms of RD and MADB progeroid syndromes, although this
mouse model does not fully recapitulate several features of these
diseases (Osorio et al., 2009). In summary, many mouse models for
laminopathies have been developed and studied in order to elucidate
the mechanisms underlying the pathogenesis of these and related
progeroid syndromes.
Several mouse models have also been created to mimic the
clinical phenotypes associated with WS. Wrn-knockout mice
have no obvious signs of accelerated senescence and fail to
recapitulate clinical WS features (Lombard et al., 2000). However,
Wrn−/−Terc−/−mice exhibit many of the key phenotypes, in support
of a role for WRN in telomere maintenance (Chang et al., 2004).
Mouse models of BS have also been developed, but their early
lethality has hampered their utility for the in vivo study of this
disease (Luo et al., 2000). Likewise, mice bearing the most common
mutations found in RTS individuals have been generated. These
mice show severe growth retardation, hair loss, dry skin and
increased cancer susceptibility (Mann et al., 2005). Mutant mice
have been developed for all CS-associated genes, most of which
Table 3. Main mouse models used for the study of progeroid syndromes
Syndrome Gene Phenotype References
HGPS Zmpste24 Growth retardation, cardiomyopathy, muscular dystrophy, lipodystrophy,
bone fractures, premature death. Mosaic Zmpste24 mice show no
progeroid phenotype nor shortened lifespan
Bergo et al., 2002; de la Rosa et al.,
2013; Pendas et al., 2002; Ugalde
et al., 2011
HGPS Zmpste24,
Tp53
Partial rescue of progeroid phenotypes Varela et al., 2005
HGPS Lmna LmnaG609G mice phenocopy most HGPS features Osorio et al., 2011
WS Wrn No obvious signs of accelerated senescence Lombard et al., 2000
WS Wrn, Tp53 Wrn−/−Tp53−/− mice have an increased mortality rate Lombard et al., 2000
WS Wrn, Terc Premature death, hair greying, alopecia, diabetes osteoporosis,
cataracts, low bone mass and cancer
Chang et al., 2004
Singh et al., 2013
RTS Recql4 Phenocopies main clinical manifestations of RTS Mann et al., 2005
CS Ercc6, Ercc8 Reduced fat tissue, photoreceptor cell loss and mild nervous system
pathology
Jaarsma et al., 2013
XP Xpa, Xpc Xpc−/− mice: reduced lifespan and increased incidence of cancer
Xpa−/− mice: no lifespan changes but increased incidence of cancer
Melis et al., 2008
XP Ercc5 Slow growth, loss of subcutaneous fat, kyphosis, osteoporosis, retinal
photoreceptor loss, liver ageing, neurodegeneration and short lifespan
Barnhoorn et al., 2014
XP Ercc1 Chronic inflammation, adipose tissue depletion and lipodystrophy Karakasilioti et al., 2013
TTD Ercc2 Developmental abnormalities, brittle hair, reduced lifespan, UV sensitivity
and skin abnormalities
de Boer et al., 1998
FA Fancd2 Embryonic or perinatal lethality, cancer susceptibility, hematological and
gonadal abnormalities
Houghtaling et al., 2003; Langevin et al.,
2011
SS Atr Embryonic replicative stress and accelerated ageing, further aggravated
in the absence of p53
Murga et al., 2009
AT Atm Growth retardation, infertility, T-cell defects, osteopenia and increased
cancer susceptibility
Barlow et al., 1996; Hishiya et al., 2005
DC Terc,
Pot1b
Progressive bone-marrow failure, hyperpigmentation and early death Hockemeyer et al., 2008
HGPS, Hutchinson-Gilford progeria syndrome; WS, Werner syndrome; RTS, Rothmund-Thomson syndrome; CS, Cockayne syndrome; XP, xeroderma
pigmentosum; TTD, trichothiodystrophy; FA, Fanconi anaemia; SS, Seckel syndrome ; AT, ataxia telangiectasia; DC, dyskeratosis congenita.
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develop mild CS-like symptoms (Jaarsma et al., 2013). Mice mutant
for Xpa−/− and Xpc−/− have also been reported. Xpc−/− mice
demonstrate a reduced lifespan and an increased rate of lung cancer,
whereas Xpa−/− mice show no lifespan alterations but exhibit a
higher rate of liver carcinomas (Hosseini et al., 2015; Melis et al.,
2008). Xpg-deficient mice also display many progeroid features,
including loss of subcutaneous fat, osteoporosis, neurodegeneration
and a short lifespan (Barnhoorn et al., 2014). Furthermore, DNA
damage in mice carrying an Ercc1-Xpf DNA-repair defect triggers a
chronic inflammatory response, leading to lipodystrophy
(Karakasilioti et al., 2013). Finally, a mouse model of TTD
recapitulates the human disorder, demonstrating developmental
defects, brittle hair, UV sensitivity, skin abnormalities and reduced
lifespan (de Boer et al., 1998).
There are several FA mouse models, all of which are
characterized by embryonic or perinatal lethality, gonadal
abnormality and associated infertility (Bakker et al., 2013).
Nevertheless, most FA mouse models do not show any apparent
hematological abnormalities, in contrast with humans with FA, who
are affected by life-threatening anaemia. An exception to this is the
Fancp mutant mouse, which has lowered numbers of white blood
cells and platelets (Langevin et al., 2011). Hematopoietic stem cells
(HSCs) from other FA mouse mutants (Fancc, Fancd2 and Fancg)
have a reduced repopulating ability and fail to maintain
hematopoietic homeostasis under stress conditions (Bakker et al.,
2013). Fancd2-, Fancf- or Fancm-deficient mice also exhibit an
increased incidence of tumorigenesis (Bakker et al., 2013). The SS
mouse model, characterized by ATR deficiency, shows high levels
of replicative stress during embryogenesis and exhibits accelerated
ageing, which is further aggravated in a Tp53-null background
(Murga et al., 2009). AT mouse models recapitulate many of the
characteristics observed in humans with AT, such as growth
retardation, infertility, immune defects and increased susceptibility
to lymphomas, although neurodegeneration is not observed
(Barlow et al., 1996). Additionally, Atm-deficient mice show
increased cancer susceptibility and a severe osteopenic phenotype,
which is partly caused by a stem cell defect due to decreased
expression of IGF, an important regulator of proliferation (Hishiya
et al., 2005).
Mouse models of telomere dysfunction in progeroid syndromes
have also been generated. The first mutant mouse with telomerase
deficiency failed to recapitulate the clinical features of DC.
However, when POT1b−a component of the shelterin complex
that protects mammalian telomeres−is removed in mice (Box 1),
these animals show clinical features of DC (Hockemeyer et al.,
2008). Mouse models of APS, HHS, NBN, ATLD or CRMCC are
yet to be developed.
Hallmarks of progeroid syndromes
Based on the evidence obtained through experimentation with
cellular and animal models, we propose a set of hallmarks for
defining the main features of progeroid syndromes, and discuss their
relatedness and differences with those of normal ageing (Fig. 3).
Defining these molecular hallmarks could help in the design and
interpretation of future studies of both physiological and premature
ageing, and could also provide clinical benefit by guiding the
diagnosis of or therapy for progeroid diseases.
Increased DNA damage and defective DNA repair
Both physiologically aged and progeroid cells accumulate genomic
damage throughout life (Vijg and Suh, 2013). Somatic mutations
and other forms of DNA damage progressively compile within cells
from both aged humans and model organisms, affecting essential
genes and resulting in dysfunctional cells and impaired organismal
homeostasis (Lopez-Otin et al., 2013). Many other age-related
changes can also affect DNA repair mechanisms, leading to the
accumulation of more genomic damage (Gorbunova et al., 2007).
HGPS and RD progeroid cells are particularly susceptible to DNA
damage induced by ROS or by ionizing radiation, and show a
severely impaired capacity to repair DNA damage (Camozzi et al.,
2014). Many progeroid syndromes also present repair defects owing
to mutations in RecQ helicases (Box 1), or in proteins belonging
to the ERCC and XP families (Bernstein et al., 2010; Marteijn
et al., 2014).
Telomere dysfunction
Telomere shortening is observed during normal ageing in both
human and mouse cells, and has been linked to a decreased lifespan
(Blasco et al., 1997). As discussed earlier, progeroid syndromes such
as DC and HHS are caused by mutations in different components of
the telomerase complex. Other ageing-related diseases, such as WS,
FA, SS, AT, ATLD, NBN and CRMCC, are characterized by
telomere dysfunction caused by mutations in genes involved in
telomere maintenance and DNA repair (Armanios and Blackburn,
2012). HGPS cells also exhibit accelerated telomere shortening
during proliferation in culture (Decker et al., 2009). Notably, the
ectopic expression of telomerase in these cells increases their
proliferation and lifespan by decreasing progerin-induced activation
of the p53 and retinoblastoma (Rb) pathways (Kudlow et al., 2008).
Additionally, the association of the shelterin TRF2 (telomere repeat-
binding factor 2) with telomeric sequences is stabilized by its
colocalization with A-type lamins. LMNA mutations lead to the
impaired association of these lamins with TRF2, resulting in
telomere loss (Wood et al., 2014). Furthermore, the ectopic
expression of progerin in normal fibroblasts results in the
accumulation of DNA damage at telomeres and in cell senescence
(Cao et al., 2011). These studies suggest that telomere dysfunction
and associated defective DNA repair contribute to genomic
instability and premature senescence of cells in progeroid syndromes.
Fig. 3. The molecular and cellular hallmarks of progeroid syndromes.
These nine proposed hallmarks recapitulate the most remarkable features
common to different progeroid syndromes and define the mechanisms
underlying the pathogenesis of these diseases.
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Changes in epigenetics and chromatin structure
Chromatin remodelling plays a central role in the regulation of gene
expression. As such, altered chromatin structure can lead to aberrant
gene expression patterns, altering normal cellular functions and
contributing to both normal and premature ageing (Chandra et al.,
2015). Aged cells also accumulate epigenetic alterations that alter
normal gene expression profiles (Beerman and Rossi, 2015).
Accordingly, aged cells exhibit increased levels of histone
modifications that promote transcription and global histone loss,
inducing chromatin relaxation and the misregulation of gene
expression. Such epigenetic changes are present also in cells from
prematurely ageing individuals and likely contribute to the
progression of the associated diseases (Lopez-Otin et al., 2013).
In addition, the downregulation of chromatin remodelling factors,
such as HP1α (heterochromatin protein 1 alpha), polycomb proteins
and the NuRD complex, occurs during normal ageing and leads to
global heterochromatin loss (Pollina and Brunet, 2011). In the
context of premature-ageing syndromes, the absence of WRN (in
WS) or the accumulation of progerin (in HGPS) also causes loss of
heterochromatin and telomere attrition (Shumaker et al., 2006;
Zhang et al., 2015). Likewise, cells from NGPS individuals exhibit
profound changes in chromatin organization (Loi et al., 2016). In
cells from individuals with HGPS, the epigenetic mark H3K27me3
is lost on the inactive X chromosome of affected females, as a
consequence of downregulation of EZH2 (enhancer of Zeste
homolog 2), the methyltransferase responsible for this mark.
HGPS cells also exhibit the downregulation of H3K9me3 but
increased levels of H4K20me3, which are epigenetic modifications
that are associated with global repression of transcription
(Shumaker et al., 2006). However, in a different study, increased
levels of H3K9me3 were linked to accelerated senescence and
compromised genome maintenance (Liu et al., 2013).
Sirtuin 1 (SIRT1) is thought to contribute to telomere
maintenance through deacetylation of epigenetic marks such as
H4K16ac (Palacios et al., 2010). By contrast, low levels of
acetylation at H4K16 have been shown to correlate with a
defective DNA-damage response (DDR) and double-strand-break
repair to ionizing radiation (Sharma et al., 2010). In line with this,
Zmpste24−/− mice show hypoacetylation of histones H2B and H4
(Osorio et al., 2010), likely due to the diminished association of the
histone acetyltransferase Mof (male absent on the first) with the
nuclear matrix. Rescue experiments performed either by Mof
overexpression or by histone deacetylase inhibition promoted repair
protein recruitment to DNA damage sites and substantially
ameliorated aging-associated phenotypes in these mice (Krishnan
et al., 2011).
Heterochromatin alterations have also been observed in other
syndromes, such as an active heterochromatinization process
mediated by SIRT1 in XP or CS cells after UV irradiation (Velez-
Cruz et al., 2013), and the presence of unstable heterochromatin in
FA cells (Edelman and Lin, 2001). Although epigenetic changes
have not yet been identified in all progeroid syndromes, the
frequent occurrence of both epigenetic and chromatin alterations
tempt us to speculate that such defects are general features of these
diseases.
Aberrant nuclear architecture
Several progeroid syndromes−including HGPS, NGPS, APSs, RD
and MAD−are associated with significant perturbations in nuclear
organization and loss of nuclear envelope stability. In the case of
HGPS, the presence of the farnesyl group in progerin, owing to the
aberrant processing of lamin A, leads to progerin association with
the inner nuclear membrane, generating defects in nuclear shape
(Fig. 1) (Goldman et al., 2004). Such features are also observed in
healthy ageing individuals owing to the sporadic activation of the
same cryptic splice site in LMNA as in HGPS, whereas inhibition of
this splice site reverses the nuclear defects associated with ageing
(Righolt et al., 2011; Scaffidi and Misteli, 2006). Several studies
have suggested that alterations in the nuclear lamina might lead to
premature ageing by affecting the transcription profile of adult
epithelial and mesenchymal stem cells and thereby interfering with
their ability to retain an undifferentiated state (Espada et al., 2008;
Scaffidi and Misteli, 2008). Progeroid fibroblasts obtained from
NGPS individuals also show profound abnormalities in the nuclear
lamina (Fig. 1) that can be rescued by the ectopic expression of
wild-type BANF1 (Puente et al., 2011; Soria-Valles et al., 2015a).
Furthermore, cells from individuals with RD show an abnormal
nuclear shape and heterogeneous deposits of unprocessed prelamin
A (Columbaro et al., 2010). Severe nuclear morphological
abnormalities are also observed in MAD and APS cells
(Barthelemy et al., 2015). Collectively, these findings highlight
the relevance of nuclear lamina aberrations as important features of
different progeroid syndromes.
Defects in cell cycle and mitosis
Cell cycle regulation is critically important for repairing genetic
damage and preventing uncontrolled cell division. Changes in cell
cycle dynamics, such as upregulation of p16 and other cell cycle
inhibitors, are observed during physiological ageing and cellular
senescence, and consequently represent valuable markers for the
ageing process (Coppe et al., 2011). Nuclear envelope changes
during cell division play a major role in the control of cell cycle
progression (Camozzi et al., 2014). Accordingly, the targeting of
nuclear lamina components into daughter cell nuclei in early G1 and
cytokinesis progression is impaired in HGPS cells owing to the
abnormal processing of lamin A (Dechat et al., 2007). FA proteins
are essential for arresting the cell cycle until DNA damage is
restored; thus, cells from FA patients have defects in DNA repair
(Bogliolo and Surralles, 2015). Individuals with SS display an
impaired G2/M checkpoint arrest and an increased number of
centrosomes in mitotic cells (Griffith et al., 2008). Moreover,
insufficiency of BubR1, a key mitotic checkpoint protein, causes
aneuploidy, short lifespan, cachectic dwarfism, cataracts and other
progeroid features (Baker et al., 2004).
Cellular senescence
Cellular senescence is a state of stable cell cycle arrest and loss of
replicative capacity that mainly results from DNA damage,
oxidative stress and telomere shortening (van Deursen, 2014). In
HGPS cells, progerin-induced senescence has been partially linked
to p53 activation, a feature that is recapitulated in mouse models of
this progeroid syndrome (Varela et al., 2005). Cells from NGPS
patients also show premature cellular senescence characterized by
markers such as senescence-associated β-galactosidase (SA-β-gal)
staining, senescence-associated heterochromatin foci, increased
levels of p16 and significant loss of lamin B1 (Soria-Valles et al.,
2015a). Individuals affected by APS also present senescence
phenotypes, driven by a dramatic reduction in lamin B1 expression
(Bercht Pfleghaar et al., 2015). Likewise, fibroblasts from WS and
SS patients show premature cellular senescence induced by
replicative stress and faulty DNA repair, primarily due to the
activation of stress kinase p38 (Davis et al., 2007; Tivey et al.,
2013). Increased SA-β-gal staining and higher expression of p16
and p21 are also observed in BLM-, WRN- and RECQL4-depleted
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human fibroblasts (Lu et al., 2014). Furthermore, cells from Xpc−/−
mice show increased β-galactosidase activity and high levels of
progerin, p16 and ROS (Hosseini et al., 2015). Moreover, a mouse
model of SS, characterized by a severe deficiency in ATR, shows
accelerated ageing that is further aggravated by the loss of p53
(Murga et al., 2009). Hematopoietic stem cell senescence has also
been reported in DC and FA (Stockklausner et al., 2015; Zhang
et al., 2007).
Metabolic defects
The ageing process is accompanied by many metabolic alterations,
such as insulin resistance and physiological decline in growth
hormone (GH), insulin-like growth factor-1 (IGF-1) and sex steroids.
Accordingly, the insulin and IGF-1 signalling (IIS) pathway is
extensively involved in ageing (Lopez-Otin et al., 2013). Moreover,
dietary restriction (DR) increases healthspan in many organisms,
further supporting a role for metabolism in ageing (Barzilai et al.,
2012). Progeroid syndromes are also accompanied by metabolic
changes. Zmpste24−/− mice exhibit profound transcriptional
alterations in circulating levels of GH and IGF-1 (Marino et al.,
2010), as well as changes in metabolic pathways that are associated
with autophagy induction (Marino et al., 2008). Metabolic alterations
are also present in progeroid syndromes that feature defects in DNA
repair. Wrn-deficient mice exhibit hypertriglyceridemia and insulin
resistance (Lebel and Leder, 1998). ERCC1-null mice show a shift
toward anabolism and decreased GH-IGF-1 signalling (Niedernhofer
et al., 2006), whereas CS mouse models show systemic suppression
of the GH-IGF-I somatotropic axis (Box 1), increased antioxidant
responses and hypoglycaemia (van der Pluijm et al., 2007). These
studies suggest that unrepaired DNA damage induces a highly
conserved metabolic response that is mediated by the IIS pathway,
which redistributes resources from growth and proliferation for the
preservation and protection of somatic integrity (Liao and Kennedy,
2014; Schumacher et al., 2009). Furthermore, mice with telomere
dysfunction exhibit a marked deficiency in IGF-I-mTOR signalling,
impaired energy homeostasis and suppressed mitochondrial
biogenesis (Missios et al., 2014). Notably, mitochondrial
dysfunction has been linked to the pathogenesis of progeroid
syndromes such as HGPS and CS (Rivera-Torres et al., 2013;
Scheibye-Knudsen et al., 2013). Cells derived from HGPS patients
show a marked downregulation of mitochondrial oxidative
phosphorylation proteins, accompanied by mitochondrial
dysfunction (Rivera-Torres et al., 2013). These metabolic and
mitochondrial alterations have inspired the development of different
strategies for the treatment of progeroid syndromes (discussed below).
Inflammation
Chronic inflammation is associated with normal and pathological
ageing (Lopez-Otin et al., 2013). In line with this, a pro-
inflammatory phenotype, named ‘inflammageing’, has been
observed in mammals during ageing (Salminen et al., 2012).
Moreover, senescent cells exhibit a senescence-associated secretory
phenotype (SASP) characterized by the secretion of increasing
levels of factors that alter their microenvironment in a paracrine
manner, reinforcing senescence and activating immune
surveillance. This phenomenon is mainly regulated by NF-κB
(Acosta et al., 2013; Chien et al., 2011). We have recently found that
the aberrant activation of NF-κB by ATM in mouse models of
progeroid laminopathies induces the overexpression of pro-
inflammatory cytokines and contributes to the pathogenesis of
these syndromes (Osorio et al., 2012). Likewise, knocking down
Nfkb1 in mice causes premature ageing. Accordingly, the
accumulation of senescent cells in Nfkb1−/− tissues is blocked by
the administration of anti-inflammatory drugs to these mice (Jurk
et al., 2014). A recent study has also demonstrated that age-
associated NF-κB hyperactivation impairs the generation of iPSCs
by evoking the reprogramming repressor DOT1L, which promotes
senescence signals and downregulates pluripotency genes (Soria-
Valles et al., 2015a). An inflammatory phenotype associated with
premature ageing has also been linked to WS (Goto et al., 2012).
Similarly, mouse models of FA show inflammation-mediated
upregulation of Notch signalling, which correlates with a
decreased self-renewal capacity of FA HSCs (Du et al., 2013).
Stem cell exhaustion
The ageing process is accompanied by a decrease in tissue
regeneration and homeostasis, due to a decline in stem cell
functions as a consequence of DNA damage, changes in tissue
environment and alterations in tumour suppressor gene expression
(Behrens et al., 2014). Because stem cells regenerate many adult
tissues, changes in these cells likely contribute to the development
of age-related diseases and to accelerated ageing syndromes.
Consistent with this, progerin accumulation reduces the
proliferative and differentiation capacity of pluripotent and
multipotent (Box 1) mouse and human cells (Pacheco et al.,
2014; Rosengardten et al., 2011). Furthermore, muscle-derived
stem/progenitor cells (MDSPCs) from old and progeroid mice have
proliferation and differentiation defects, whereas intraperitoneal
administration of MDSPCs from young wild-type mice to progeroid
mice confers a significant extension of lifespan and health via the
secretion of certain factors that act systemically (Lavasani et al.,
2012). Hematopoietic stem cell senescence has been described in
the context of many progeroid syndromes. For example, TERT
mutations that cause DC lead to cellular senescence and to the loss
of CD34+ hematopoietic stem cells (Stockklausner et al., 2015).
Moreover, TNFα induces premature senescence in bone marrow
HSCs and in other tissues of FA mouse models. This induction
correlates with ROS accumulation and oxidative DNA damage
(Zhang et al., 2007). Together, these studies demonstrate the close
relationship between progeroid syndromes and stem cell exhaustion,
highlighting the importance of using cellular models to further
understand the underlying pathobiology of these diseases and to
guide the development of appropriate therapies.
Therapeutic and rejuvenation strategies
Our improved understanding of the molecular basis of the progeroid
syndromes has guided the development of therapeutic strategies for
these disorders, particularly for HGPS (Gordon et al., 2014).
Because progerin is permanently farnesylated, the first therapeutic
strategy for treating HGPS involved the use of farnesyltransferase
inhibitors (FTIs), such as lonafarnib, which has been used as a
potential anticancer drug and had tolerable side effects in children.
However, lonafarnib led to only limited improvements of symptoms
in HGPS patients (Gordon et al., 2012), in part because, following
FTI treatment, progerin is geranylgeranylated and gives rise to
another toxic form of prelamin A (Varela et al., 2008).
Consequently, an efficient blockade of progerin farnesylation
must prevent both farnesylation and geranylgeranylation
modifications, which provides the rationale behind a combined
therapeutic approach that uses statins and aminobisphosphonates
(Varela et al., 2008). This strategy has been successfully tested in
Zmpste24−/−mice and is currently being evaluated for the treatment
of individuals with HGPS (clinical trials: NCT00425607,
NCT00879034 and NCT00916747).
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Since these first strategies for HGPS treatment were described,
additional therapies have been tested, with promising results, in
mouse and cellular models of premature ageing. Many of these
interventions derive from recent anti-ageing approaches designed to
address alterations in cellular processes, such as nutrient-sensing,
mitochondrial efficiency and autophagy, which are, as highlighted
above, also deficient in progeria (de Cabo et al., 2014; Lopez-Otin
et al., 2013). One such approach is treatment with the mTOR
inhibitor rapamycin, which can suppress nuclear structure defects
and postpone senescence in HGPS fibroblasts in vitro by inducing
progerin clearance through autophagy (Cao et al., 2011).
Additionally, the SIRT1 activator resveratrol rescues adult stem
cell decline, slows down body weight loss and extends lifespan in
Zmpste24−/− progeroid mice (Liu et al., 2012). Likewise, the
administration of IGF-I to these mice has proven to positively affect
both their health and lifespan (Marino et al., 2010).
Beyond these metabolic interventions, and because HGPS is
caused by the activation of an alternative splice site, RNA therapy is
another option for the treatment of progeria. Morpholino antisense
oligonucleotides targeted to the altered splice site were first applied
in HGPS fibroblasts to reduce progerin synthesis (Scaffidi and
Misteli, 2005). This approach was also successfully used in the
LmnaG609G HGPS mouse model, in which it led to a significant
lifespan extension (Osorio et al., 2011). More recently, DOT1L
inhibitors have proven to be effective as a rejuvenation strategy for
both physiologically aged and HGPS and NGPS progeroid human
cells (Soria-Valles et al., 2015a), and the treatment of Zmpste24−/−
mice with DOT1L inhibitors increases their longevity and
ameliorates their progeroid phenotypes (Soria-Valles et al.,
2015a). Moreover, treatment of HGPS cells with a small molecule
called ‘remodelin’, which targets the acetyltransferase NAT10,
improves nuclear architecture and overall fitness of these progeroid
cells (Larrieu et al., 2014). Other potentially beneficial HGPS
treatments studied in cell-based and animal models include the
administration of sodium salicylate, which inhibits the IκB kinase
(IKK) complex (Osorio et al., 2012), pyrophosphate (Villa-Bellosta
et al., 2013), methylene blue (Xiong et al., 2016) and Icmt inhibitors
(Ibrahim et al., 2013).
Treatment with rapamycin has also been proposed as a
therapeutic strategy for MAD because it efficiently triggers
lysosomal degradation of farnesylated prelamin A (Camozzi et al.,
2014). Resveratrol has proven to be efficient in reversing some of
the clinically relevant phenotypes in Wrn-deficient mice, such as
insulin resistance and liver steatosis, although it did not improve
hypertriglyceridemia or inflammatory stress, nor extend the
lifespan of these mice. Resveratrol-treated mutant mice also
exhibited an increase in the frequency of different tumours (Labbe
et al., 2011), and failed to show improvements in HGPS-
associated bone defects (Strandgren et al., 2015). A high-fat diet
rescues the metabolic, transcriptomic and behavioural phenotypes
of a CS mouse model, whereas β-hydroxybutyrate, PARP (poly
ADP ribose polymerase) inhibition and NAD+ supplementation
can also rescue CS-associated phenotypes through activation of
SIRT1, which is involved in cell cycle regulation and response to
stressors (Scheibye-Knudsen et al., 2014). The reversal of
mitochondrial defects in CS-derived cells using serine protease
inhibitors has also been described (Chatre et al., 2015). Similarly,
a glucose-enriched diet ameliorates the impaired energy
homeostasis phenotype observed in mice with telomere
dysfunctions, through the activation of glycolysis, mitochondrial
biogenesis and oxidative glucose metabolism (Missios et al.,
2014).
Recently, the clearance of senescent cells has been proposed as a
promising strategy to promote healthy ageing, mainly through the
administration of so-called ‘senolytic’ pharmacological agents that
induce the death of senescent cells (Roos et al., 2016). Clearance of
such cells in BubR1 hypomorphic progeroid mice delayed the onset
of their ageing phenotype and attenuated its progression (Childs
et al., 2015). Selective clearance of senescent cells was also shown
to be an effective strategy for rejuvenation of tissue stem cells in
normally ageing mice (Chang et al., 2016).
Read-through of premature termination codons in cells from WS
and XP patients has been achieved using aminoglycosides: this
restores WRN functionality in WS cells (Agrelo et al., 2015) and
increases XPC protein production in XP cells (Kuschal et al., 2015).
Genetic approaches have also been used to correct XP human cells
(Dupuy and Sarasin, 2015), whereas genetic depletion of one allele
of the p65 subunit of NF-κB or treatment with IKK inhibitors delays
the age-related symptoms and pathologies of XFEPS (XPF-ERCC1
progeroid syndrome) mice, which harbour mutations in ERCC1
(involved in DNA excision repair) (Tilstra et al., 2012).
Another therapeutic option is the synthetic steroid danazol, which
has anti-gonadotropic and anti-estrogenic activities and is capable
of slowing down the progression of pulmonary fibrosis in
individuals with DC (Zlateska et al., 2015). In the case of FA,
treatment with p38 MAP-kinase inhibitors has improved the
repopulating ability of Fancc-deficient HSCs (Saadatzadeh et al.,
2009). Resveratrol also partially rescues the reduced repopulating
ability of Fancd2-deficient HSCs (Zhang et al., 2010). Treating SS
fibroblasts with p38 inhibitors can also restore their reduced
replicative capacity in vitro and ameliorate their aged morphology
(Tivey et al., 2013).
Importantly, recent studies suggest that the rate of ageing cannot
only be modified by environmental and genetic factors, but also
reversed (Freije and Lopez-Otin, 2012; Rando and Chang, 2012).
Many rejuvenation strategies are based on epigenetic
reprogramming, such as depletion of the methyltransferase
Suv39h1, which reduces H3K9me3 levels, improves DNA repair
capacity and delays senescence in progeroid cells, and also extends
lifespan in progeroid mice (Ibrahim et al., 2013; Liu et al., 2013). In
the future, strategies developed to treat progeroid syndromes could
also be considered as treatments for pathologies associated with
physiological ageing, as long as they share the same mechanisms.
This would certainly expand the benefits of these discoveries to a
wider medical community. Although many treatment options for
individuals with ageing pathologies have been successfully tested in
cellular and animal models, initiating therapeutic trials for rare
diseases such as progeroid syndromes is an exceptionally difficult
task because of the absence of longitudinal studies on different
cohorts of patients. Also, the occurrence of only a low number of
cases in any given country requires the setting up of clinical trials
that follow identical protocols in different parts of the world (Osorio
et al., 2011).
Conclusions
Over recent years, advancements in our understanding of the genetic
and molecular bases of premature aging disorders through the use of
cellular and mouse models have led to a better understanding of the
onset and progression of their clinical manifestations. On the basis
of these studies, we have herein classified progeroid syndromes in
two main categories, depending on the key molecular mechanisms
involved. This classification scheme could provide a framework for
the better understanding of the aetiology, biology and pathogenesis
of progeroid syndromes. We have also appraised the latest findings
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made through the use of in vitro and in vivo models, which have
helped to elucidate the processes that contribute to pathological
and physiological ageing, and to characterize the cellular and
organismal phenotypes of progeroid syndromes. Consequently, we
have proposed nine hallmarks that characterize most progeroid
syndromes, which extensively correlate with the nine hallmarks of
ageing recently proposed (Lopez-Otin et al., 2013). Such hallmarks
compile the most notable characteristics of progeroid syndromes
and define the mechanisms underlying their pathogenesis, which
might contribute to laying the groundwork for future studies on
physiological and pathological ageing.
Finally, we have highlighted emerging therapies that could help
to ameliorate the accelerated ageing phenotypes that underpin
progeroid syndromes. It is well known that setting up of therapeutic
trials for rare diseases is a difficult task owing to the lack of clinical
correlational studies with similar evaluation guidelines and
sufficient cohorts of patients (Osorio et al., 2011). This can
present an obstacle to the testing of therapeutic approaches
developed based on findings in cell- and animal-based studies.
Nonetheless, a deeper characterization of the genetics and
mechanisms underlying progeroid syndromes might enable earlier
diagnosis and a better understanding of how the disease will
progress in specific individuals, providing opportunities for earlier
intervention and personalized treatment. Moreover, research
focused on delaying or ameliorating physiological ageing could
also contribute to developing a suitable therapeutic approach for
progeroid syndromes.
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